GZBL(SZ:002424) Zheng Quan Zhi Xing·2025-08-19 16:22Financial Overview - The total assets of Guizhou BaiLing Pharmaceutical Group Co., Ltd. amounted to CNY 6,863,503,681.25 at the end of the reporting period, a decrease from CNY 7,134,925,658.08 at the beginning of the period [1][4] - Total liabilities decreased to CNY 3,586,778,548.57 from CNY 3,935,723,314.43, indicating a reduction in financial obligations [2][4] - The total equity increased to CNY 3,276,725,132.68 from CNY 3,199,202,343.65, reflecting a growth in shareholder value [2][4] Revenue and Profitability - The total operating revenue for the first half of 2025 was CNY 1,461,977,449.93, down from CNY 2,142,835,969.60 in the same period of 2024, representing a decline of approximately 31.7% [4][5] - Operating costs also decreased to CNY 1,363,394,630.11 from CNY 2,001,326,614.23, showing a reduction of about 31.9% [4][5] - The net profit for the first half of 2025 was CNY 52,435,926.96, down from CNY 84,193,692.89 in the previous year, indicating a decline of approximately 37.7% [5][6] Cash Flow Analysis - The net cash flow from operating activities was CNY 249,349,377.36, a significant improvement compared to a negative cash flow of CNY -30,370,447.37 in the same period last year [6][7] - Cash and cash equivalents at the end of the reporting period increased to CNY 470,025,070.63 from CNY 310,878,663.68, indicating a positive cash position [7] Asset Management - Current assets totaled CNY 3,376,150,287.46, down from CNY 3,643,636,271.90, reflecting a decrease in liquidity [1][3] - Inventory levels decreased to CNY 871,435,318.25 from CNY 1,111,261,175.58, indicating improved inventory management [1][3] Liabilities Management - Short-term borrowings increased to CNY 1,523,264,184.22 from CNY 1,432,241,882.40, suggesting a rise in reliance on short-term financing [2][4] - The total current liabilities decreased to CNY 3,359,237,298.13 from CNY 3,799,824,847.07, indicating a reduction in short-term financial obligations [2][4]